Iñaki Gutiérrez-Ibarluzea, N. Bolaños, Jan Geissler, Giovanni Gorgoni, Tara Lumley, Joseph Mikhael, Tamara Milagre, H. Poppel, L.E.K Consultant, Consulting
{"title":"超越总生存期:肿瘤相关终点在HTA机体/支付者决策中的价值","authors":"Iñaki Gutiérrez-Ibarluzea, N. Bolaños, Jan Geissler, Giovanni Gorgoni, Tara Lumley, Joseph Mikhael, Tamara Milagre, H. Poppel, L.E.K Consultant, Consulting","doi":"10.29011/2574-710x.10181","DOIUrl":null,"url":null,"abstract":"Introduction : HTA bodies/payers have focused on overall survival (OS) to evaluate oncology medicine’s efficacy during decision-making. While OS remains important, reliance on it poses three challenges: potential delayed patient access to medicines due","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"57 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Beyond Overall Survival: The Value of Oncology- Relevant Endpoints in HTA Body / Payer Decision-Making\",\"authors\":\"Iñaki Gutiérrez-Ibarluzea, N. Bolaños, Jan Geissler, Giovanni Gorgoni, Tara Lumley, Joseph Mikhael, Tamara Milagre, H. Poppel, L.E.K Consultant, Consulting\",\"doi\":\"10.29011/2574-710x.10181\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction : HTA bodies/payers have focused on overall survival (OS) to evaluate oncology medicine’s efficacy during decision-making. While OS remains important, reliance on it poses three challenges: potential delayed patient access to medicines due\",\"PeriodicalId\":73876,\"journal\":{\"name\":\"Journal of oncology research and therapy\",\"volume\":\"57 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-08-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of oncology research and therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.29011/2574-710x.10181\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of oncology research and therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29011/2574-710x.10181","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Beyond Overall Survival: The Value of Oncology- Relevant Endpoints in HTA Body / Payer Decision-Making
Introduction : HTA bodies/payers have focused on overall survival (OS) to evaluate oncology medicine’s efficacy during decision-making. While OS remains important, reliance on it poses three challenges: potential delayed patient access to medicines due
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
